(NASDAQ: RPRX) Royalty Pharma's forecast annual revenue growth rate of 19.37% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 133.62%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.87%.
Royalty Pharma's revenue in 2025 is $2,263,845,000.On average, 2 Wall Street analysts forecast RPRX's revenue for 2025 to be $1,668,042,060,783, with the lowest RPRX revenue forecast at $1,651,247,381,708, and the highest RPRX revenue forecast at $1,684,837,302,099. On average, 2 Wall Street analysts forecast RPRX's revenue for 2026 to be $1,800,947,789,011, with the lowest RPRX revenue forecast at $1,744,214,934,668, and the highest RPRX revenue forecast at $1,857,681,205,595.
In 2027, RPRX is forecast to generate $1,972,307,378,197 in revenue, with the lowest revenue forecast at $1,957,741,981,788 and the highest revenue forecast at $1,986,872,774,606.